beta-amyloid protein


Also found in: Medical.

be·ta-am·y·loid protein

 (bā′tə-ăm′ə-loid′, bē′-)
n.
An amyloid that circulates in human blood and in cerebrospinal fluid and is deposited into plaques found in the brains of patients with Alzheimer's disease. Also called amyloid beta-protein.

[From the beta sheets characterizing its structure.]
Mentioned in ?
References in periodicals archive ?
Signs of the beta-amyloid protein were found in the brains of seven patients aged 36 to 51 who had died from Creutzfeldt-Jakob Disease (CJD) after receiving growth hormone from the pituitary glands of dead people.
Researcher Abha Chauhan, PhD, and associates say an extract in the nuts may provide a protective effect against oxidative damage caused by beta-amyloid protein.
In both studies, scientists looked for signs of beta-amyloid protein, which forms clumps in the brains of Alzheimer's patients and is a key hallmark of the disease.
Beta-amyloid protein is the primary material found in the sticky brain "plaques" characteristic of Alzheimer's disease.
For example, using brain PET imaging in conjunction with a specialized chemical that binds to beta-amyloid protein, the buildup of the protein as plaques in the brain can be revealed years before symptoms appear.
In Alzheimer's, the gene is assumed to affect the metabolism of the beta-amyloid protein, slowing clearance and causing it to clump onto neurons.
Professor Martins is credited, in collaboration with Australian and German scientists, with isolating beta-amyloid protein, which forms amyloid plaque deposits in the brain, a characteristic diagnostic feature of Alzheimer's disease.
Alzheimer's is marked by deposits of beta-amyloid protein in the brain, and knotty protein structures in the nerves called tau tangles.
Now, using new research techniques, scientists have shown that a two-molecule aggregate (or dimer) of beta-amyloid protein fragments may play a role in initiating the disease.
Today, the beta-amyloid protein is what most researchers believe is the cause of Alzheimer's disease.
Researchers used mice genetically engineered to accumulate waxy plaques of beta-amyloid protein in their brains, a symptom of Alzheimer's disease in people.
Besides the Company's Synuclere[TM] program, in late pre-clinical development for the treatment of Parkinson's disease, ProteoTech is developing Exebryl-1[R] for the treatment of diseases caused by beta-amyloid protein and tau protein aggregates and fibrils; and is in early human clinical studies with Systebryl[TM] for the treatment of Systemic AA Amyloidosis.